Induction-Maintenance With Atazanavir in HIV Naïve Patients (The INDUMA Study)

NCT ID: NCT00207142

Last Updated: 2010-01-12

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 252 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-11-30
• Study Completion Date: 2008-01-31

Brief Summary

The purpose of this study is to compare the proportion of subjects with HIV-1 RNA viral load < 50 c/mL through Week 48 of the Maintenance Phase among HIV-infected subjects with an initial undetectable viral load following an Induction Phase with an ATV/RTV containing HAART regimen, when switched to ATV versus remaining on ATV/RTV, whilst continuing their previous NRTI backbone.

Conditions

HIV Infections

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Switch

ATV 400 mg + 2 NRTIs (TBD), ATV once daily, NRTIs (TBD)

Group Type: ACTIVE_COMPARATOR

Atazanavir + 2 NRTIs

Intervention Type: DRUG

Capsules, tablets, Oral, 48 weeks (after a 26-to-30-week induction phase with ATV 300 mg + RTV 100 mg + 2 NRTIs)

Continuation

ATV 300 mg + RTV 100 mg + 2 NRTIs (TBD), ATV and RTV once daily, NRTIs (TBD)

Group Type: ACTIVE_COMPARATOR

Atazanavir + Ritonavir + 2 NRTIs

Intervention Type: DRUG

Capsules, tablets, Oral, 48 weeks (after a 26-to-30-week induction phase with ATV 300 mg + RTV 100 mg + 2 NRTIs)

Rescue

ATV 300 mg + RTV 100 mg + 2 NRTIs (TBD), ATV and RTV once daily, NRTIs (TBD)

Group Type: OTHER

Atazanavir + Ritonavir + 2 NRTIs

Intervention Type: DRUG

Capsules, tablets, Oral, 48 weeks (after a 26-to-30-week induction phase with ATV 300 mg + RTV 100 mg + 2 NRTIs)

Interventions

Atazanavir + 2 NRTIs

Capsules, tablets, Oral, 48 weeks (after a 26-to-30-week induction phase with ATV 300 mg + RTV 100 mg + 2 NRTIs)

Intervention Type: DRUG

Atazanavir + Ritonavir + 2 NRTIs

Capsules, tablets, Oral, 48 weeks (after a 26-to-30-week induction phase with ATV 300 mg + RTV 100 mg + 2 NRTIs)

Intervention Type: DRUG

Other Intervention Names

Reyataz; Reyataz

Eligibility Criteria

Inclusion Criteria

• Treatment naive HIV-1 infected subjects ( < 10 days of treatment with any ARV).
• Subjects who have an HIV-1 RNA level ≥ 5000 c/mL at screening.
• Subjects who have a CD4 count ≥ 50 cells/mm3.
• Men and women, ages 18 years of age or older (or minimum age as determined by local regulatory or as legal requirements dictate).
• Both females of child-bearing potential and males must utilize effective barrier contraception. Other contraception in addition to barrier methods is permitted; refer to the Investigator Brochure for details regarding potential interactions with ATV and some oral contraceptives

Exclusion Criteria

• WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 8 weeks after the study.
• WOCBP using a prohibited contraceptive method. Caution is warranted with coadministration of oral contraceptives (ethinyl estradiol and norethindrone) - see Investigator Brochure for details
• Women who are pregnant or breastfeeding
• Women with a positive pregnancy test on enrollment or prior to study drug administration.
• Presence of a newly diagnosed HIV-related opportunistic infection or any medical condition requiring acute therapy at the time of enrollment
• Primary HIV infection
• Medical History and Concurrent Diseases
• Active alcohol or substance use sufficient, in the investigator's opinion, to prevent adequate compliance with study therapy or to increase the risk of developing pancreatitis or chemical hepatitis Physical and Laboratory Test Findings
• Screening laboratory values measured as follows:
• Grade IV glucose,
• Grade IV electrolytes,
• Grade IV transaminases,
• Grade IV hematology.
• Hypersensitivity to any component of the formulation of study drug
• Prior history of taking any ARV for more than 10 days
• Concomitant administration of tenofovir (TDF).
• Refer to Section 6.4.1 which details all prohibited therapies

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Bristol-Myers Squibb

INDUSTRY

Sponsor Role: lead

Responsible Party

Bristol-Myers Squibb

Principal Investigators

Bristol-Myers Squibb

Role: STUDY_DIRECTOR

Bristol-Myers Squibb

Locations

Local Institution

Tallinn, , Estonia

Local Institution

Le Kremlin-Bicêtre, , France

Local Institution

Orléans, , France

Local Institution

Paris, , France

Local Institution

Suresnes, , France

Local Institution

Düsseldorf, , Germany

Local Institution

Hanover, , Germany

Local Institution

Stuttgart, , Germany

Local Institution

Ulm, , Germany

Local Institution

Dublin, Dublin, Ireland

Local Institution

Brescia, , Italy

Local Institution

Milan, , Italy

Local Institution

Napoli, , Italy

Local Institution

Padua, , Italy

Local Institution

Riga, , Latvia

Local Institution

Cascais, , Portugal

Local Institution

Porto, , Portugal

Local Institution

Moscow, , Russia

Local Institution

Saint Petersburg, , Russia

Local Institution

Smolensk, , Russia

Local Institution

Elche, Alicante, Spain

Local Institution

Barcelona, , Spain

Local Institution

Madrid, , Spain

Local Institution

Valencia, , Spain

Local Institution

Bristol, Avon, United Kingdom

Local Institution

Edinburgh, Central, United Kingdom

Local Institution

London, Greater London, United Kingdom

Countries

Estonia; France; Germany; Ireland; Italy; Latvia; Portugal; Russia; Spain; United Kingdom

Other Identifiers

AI424-136

Identifier Type: -

Identifier Source: org_study_id